Nepidermin
Also known as: EGF peptide, Heberprot‑P, recombinant human epidermal growth factor, rhEGF analog
Source Nepidermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human epidermal growth factor (rhEGF) formulated as a topical gel (Nepidermin) used to promote healing of diabetic foot ulcers and other skin lesions.
Mechanism of Action
Binds epidermal growth factor receptor (EGFR) on keratinocytes and fibroblasts, activating MAPK/ERK pathways that stimulate cell proliferation, migration, angiogenesis and extracellular matrix remodeling, thereby accelerating wound closure.
Routes of Administration
Goals & Uses
- Diabetic foot ulcer healingWound HealingModerate
- Post-surgical wound recoveryTissue RepairLow
- Burn wound healingWound HealingModerate
- Chronic wound closureWound HealingModerate
- diabetic foot ulcer closureWound HealingModerate
- Corneal epithelial repairOphthalmologyLow
- burn and skin graft integrationWound HealingLow
Contraindications
- known hypersensitivity to EGF or formulation excipientsAllergyHigh
- Known malignancy at or near application siteOncologyHigh
- Active wound infection (uncontrolled)Infectious DiseaseModerate
- Hypersensitivity to EGF or excipientsAllergy/immunologyHigh
- active malignant disease or proliferative skin lesionsOncologyModerate
Adverse Effects
- pain or burning at application siteSensoryCommon
- Erythema at application siteDermatologicCommon
- PruritusDermatologicUncommonItching
- infection of ulcerInfectiousRare
- Hypersensitivity/allergic reactionImmunologicalRare
- Granuloma formationLocal ReactionRare
- Local erythemaDermatologicCommon
- Local injection site pain/burningLocal ReactionCommon
- Local edemaLocal ReactionUncommon
Drug Interactions
- systemic chemotherapy agentsModerate
- EGFR inhibitors (e.g., erlotinib, cetuximab)High
- other topical growth factorsLow
- Corticosteroids (topical/systemic)Moderate
Population Constraints
- Patients with active malignanciesOncologyAbsolute
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
- Children <12 yearsAgeRelative
Regulatory Status
- European UnionInvestigationalUnder clinical investigation; not authorized for marketing.
- United StatesUnapprovedNot evaluated by FDA; available only in clinical trials.
- United KingdomUnapprovedNo marketing authorization; may be accessed via compassionate use schemes.
Approved in Cuba (Heberprot‑P) for diabetic foot ulcer; not FDA‑approved in the United States and considered investigational in the EU.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Nepidermin?
Recombinant human epidermal growth factor (rhEGF) formulated as a topical gel (Nepidermin) used to promote healing of diabetic foot ulcers and other skin lesions.
What is Nepidermin used for?
Nepidermin is educationally associated with: Diabetic foot ulcer healing, Post-surgical wound recovery, Burn wound healing, Chronic wound closure, diabetic foot ulcer closure, Corneal epithelial repair, burn and skin graft integration. Educational only — not medical advice.
How is Nepidermin administered?
Recorded routes of administration: Intralesional, Subcutaneous, Topical.
What are the potential side effects of Nepidermin?
Reported adverse effects include: pain or burning at application site, Erythema at application site, Pruritus, infection of ulcer, Hypersensitivity/allergic reaction, Granuloma formation, Local erythema, Local injection site pain/burning, Local edema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Nepidermin?
Recorded contraindications: known hypersensitivity to EGF or formulation excipients, Known malignancy at or near application site, Active wound infection (uncontrolled), Hypersensitivity to EGF or excipients, active malignant disease or proliferative skin lesions. Consult a qualified clinician before use.